Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors.
对强效且高选择性的 CDK2 抑制剂 BLU-222 的活性进行分析，揭示了 CCNE1 异常卵巢和子宫内膜肿瘤的反应决定因素
期刊:Cancer Research
影响因子:16.6
doi:10.1158/0008-5472.CAN-24-2360
House Nealia C, Brown Victoria E, Chen Maxine, Yuan Liang, Moore Sydney L, Guo Jian, Choi Yoon Jong, Muthuswamy Lakshmi, Ribich Scott, Ramsden Philip, Faia Kerrie L
